Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with high-risk alcohol consumption were equally likely to achieve a cure with direct-acting antivirals.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.
Offering hepatitis C treatment at the point of diagnosis streamlines care, saving both time and money.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
Hepatitis C prevalence was higher among people with unstable housing and those who injected drugs every day.
Only 20% of people covered by Medicaid received treatment within six months of their HCV diagnosis.
Modern antivirals can cure 95% of people with HCV, lowering the risk of cirrhosis, liver cancer and liver failure.
Older people, men and people living in poverty and lacking private insurance were more likely to have active HCV infection.
The CDC estimates that 21% of people living with HIV also have hepatitis C virus.
Drug-related mortality, including overdose, was the leading cause of death.
A “jarringly low” proportion of people with HCV have been tested, treated and cured.
The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
The three-drug combination cured most people who had experienced previous treatment failure.
People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.